JP2022111148A5 - - Google Patents

Download PDF

Info

Publication number
JP2022111148A5
JP2022111148A5 JP2022084854A JP2022084854A JP2022111148A5 JP 2022111148 A5 JP2022111148 A5 JP 2022111148A5 JP 2022084854 A JP2022084854 A JP 2022084854A JP 2022084854 A JP2022084854 A JP 2022084854A JP 2022111148 A5 JP2022111148 A5 JP 2022111148A5
Authority
JP
Japan
Prior art keywords
icos
bispecific antibody
monomer
antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022084854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022111148A (ja
Filing date
Publication date
Priority claimed from US15/623,314 external-priority patent/US10787518B2/en
Priority claimed from JP2019511464A external-priority patent/JP7080219B2/ja
Priority claimed from PCT/US2017/049497 external-priority patent/WO2018045110A1/en
Application filed filed Critical
Publication of JP2022111148A publication Critical patent/JP2022111148A/ja
Publication of JP2022111148A5 publication Critical patent/JP2022111148A5/ja
Pending legal-status Critical Current

Links

JP2022084854A 2016-08-30 2022-05-24 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 Pending JP2022111148A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201662381239P 2016-08-30 2016-08-30
US62/381,239 2016-08-30
US201762456033P 2017-02-07 2017-02-07
US62/456,033 2017-02-07
US201762479723P 2017-03-31 2017-03-31
US62/479,723 2017-03-31
US15/623,314 2017-06-14
US15/623,314 US10787518B2 (en) 2016-06-14 2017-06-14 Bispecific checkpoint inhibitor antibodies
JP2019511464A JP7080219B2 (ja) 2016-08-30 2017-08-30 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
PCT/US2017/049497 WO2018045110A1 (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019511464A Division JP7080219B2 (ja) 2016-08-30 2017-08-30 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体

Publications (2)

Publication Number Publication Date
JP2022111148A JP2022111148A (ja) 2022-07-29
JP2022111148A5 true JP2022111148A5 (cg-RX-API-DMAC10.html) 2023-02-20

Family

ID=65632988

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511464A Active JP7080219B2 (ja) 2016-08-30 2017-08-30 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
JP2022084854A Pending JP2022111148A (ja) 2016-08-30 2022-05-24 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019511464A Active JP7080219B2 (ja) 2016-08-30 2017-08-30 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体

Country Status (12)

Country Link
EP (1) EP3507306B1 (cg-RX-API-DMAC10.html)
JP (2) JP7080219B2 (cg-RX-API-DMAC10.html)
KR (2) KR20230130174A (cg-RX-API-DMAC10.html)
CN (1) CN110267990B (cg-RX-API-DMAC10.html)
AU (1) AU2017321625A1 (cg-RX-API-DMAC10.html)
CA (1) CA3035343A1 (cg-RX-API-DMAC10.html)
DK (1) DK3507306T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251424T1 (cg-RX-API-DMAC10.html)
IL (1) IL265046B2 (cg-RX-API-DMAC10.html)
MX (1) MX2023006786A (cg-RX-API-DMAC10.html)
SG (1) SG11201901712YA (cg-RX-API-DMAC10.html)
ZA (1) ZA201901752B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3044323T3 (pl) * 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
KR102170077B1 (ko) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
MX2021005048A (es) * 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
JP2023521228A (ja) * 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
KR102911451B1 (ko) * 2022-05-24 2026-01-09 건국대학교 글로컬산학협력단 Rps3 결합 단클론 항체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
KR102391731B1 (ko) * 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
ES2826566T3 (es) * 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
HK1245171A1 (zh) * 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
SMT201900702T1 (it) * 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos

Similar Documents

Publication Publication Date Title
JP2019513009A5 (cg-RX-API-DMAC10.html)
JP2022516503A5 (cg-RX-API-DMAC10.html)
JP2022504802A5 (cg-RX-API-DMAC10.html)
JP2016533763A5 (ja) ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
JP2018516554A5 (cg-RX-API-DMAC10.html)
JP2019525738A5 (cg-RX-API-DMAC10.html)
JP2022512684A5 (cg-RX-API-DMAC10.html)
JP2019518721A5 (cg-RX-API-DMAC10.html)
IL299221A (en) Cd3 binding antibodies
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
JP2022512653A5 (cg-RX-API-DMAC10.html)
JP2019513370A5 (cg-RX-API-DMAC10.html)
JP2023507729A5 (cg-RX-API-DMAC10.html)
JP2021501162A5 (cg-RX-API-DMAC10.html)
AR120741A1 (es) Anticuerpos anti-ly6g6d y métodos de uso
IL263542B1 (en) Bispecific antibodies inhibit immunological checkpoint
JP2019532017A5 (cg-RX-API-DMAC10.html)
JP2020524000A5 (cg-RX-API-DMAC10.html)
JP2018508483A5 (cg-RX-API-DMAC10.html)
IL265541B1 (en) Bispecific antibodies and compositions comprising thereof for treating cancer
RU2018107658A (ru) Новые антитела против pd-l1
JP2015163068A5 (cg-RX-API-DMAC10.html)
JP2025118688A5 (cg-RX-API-DMAC10.html)
JP2022521705A5 (cg-RX-API-DMAC10.html)
JP2024086870A5 (cg-RX-API-DMAC10.html)